Treatment shows remyelination promisePublished 08 June 2022 A new experimental treatment has been shown to promote the restoration of the myelin sheath in preclinical models of the disease. ABX-002, which is being developed by Autobahn Therapeutics, is a thyromimetic – a lab-made molecule which is designed to mimic the activity